Vasella helps Numab to CHF22M round ahead of cancer trial start

Swiss flag by a lake
Swiss biotech Numab Therapeutics’ platform supports molecules with up to six binding specificities. (Andrew Bossi/CC BY-SA 2.5)

Numab Therapeutics has raised CHF 22 million ($23.8 million) ahead of the start of clinical testing of its lead oncology drug ND021. Daniel Vasella, the former CEO of Novartis, was among the people to participate in the financing round.

In recent years, Numab has entered into a series of partnerships, landing deals with companies such as 3SBio, Eisai and Ono Pharmaceutical. The alliances tap into Numab’s ability to create multispecific antibody-based therapeutics. Like some other players in the multispecific space, Numab describes its technology as a plug-and-play platform that can quickly generate novel candidates. 

Now, Numab is closing in on the start of a clinical trial that will begin to show whether its approach can deliver on the promise that attracted a string of partners. The trial, which is due to start this year, will test PD-L1x4-1BBxHSA trispecific ND021 in cancer patients.

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

With the clinical trial start date looming into view, Numab has raised a CHF 22 million series B round. As disclosed late last year, 3SBio-subsidiary Sunshine Guojian put CHF 15 million into the B round (PDF), making it the main contributor. Numab also received investment from Mitsubishi UFJ Capital, Eisai and Vasella, who joined the company’s board of directors last year. 

Some of the money will go toward the ND021 clinical trial. Numab is moving the candidate into the clinic in the belief simultaneously targeting PD-L1 on cancer cells and costimulatory receptor 4-1BB on T cells will deliver the efficacy of existing immuno-oncology drugs with a cleaner toxicity profile.

Other companies, including Genmab, are also working on drugs that hit PD-L1 and 4-1BB at the same time. However, Numab thinks ND021 has an edge over the competition, pointing to its affinity for PD-L1 and use of a half-life extending HSA-binding motif to make its case.

Numab will use the rest of the money to continue expanding its pipeline and moving other assets toward the clinic. The Swiss biotech’s preclinical pipeline features an anti-TNF antibody fragment to treat inflammatory bowel disease and several multispecifics against undisclosed targets involved in chronic inflammation and immuno-oncology. 

The platform behind the candidates, branded MATCH, enables Numab to go after multiple targets at once. According to Numab, the platform supports molecules with up to six binding specificities.

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Contract research organization Parexel has launched what it dubs #KeepingPatientsFirst, a new research platform powered by Microsoft Azure.